What the label measured
Section 6.1 reports hypoglycemia trial by trial, because the two weight trials handled it differently. Trial 2 enrolled adults with type 2 diabetes on diet and exercise or diabetes tablets other than DPP-4 inhibitors or GLP-1 receptor agonists, and excluded anyone on injectable glucose-lowering medicines such as insulin [1]. Trial 1, in adults without diabetes, did not capture hypoglycemia systematically but still recorded low readings [1].
The ClinicalTrials.gov entry for Trial 2, ATTAIN-2, lists one serious event termed hypoglycaemic unconsciousness, in the group on the 6 mg trial dose that corresponds to Foundayo™ 5.5 mg, and none elsewhere [1][5]. That fits the label’s single severe episode, though the registry does not say it is the same case.
| Trial and group | Foundayo™ | Placebo or comparison |
|---|---|---|
| Trial 2, glucose below 54 mg/dL | 2% | 0.2% (placebo) |
| Trial 2, Foundayo™ with or without a sulfonylurea | 7% with | 0.5% without |
| Trial 2, severe hypoglycemia | 1 person (5.5 mg) | none (placebo) |
| Trial 1, glucose below 54 mg/dL | 0.6% | none (placebo) |
Who carries the most risk
The clearest signal is the sulfonylurea effect. Section 7.2 explains that Foundayo™ stimulates insulin release when glucose is high, which can add to insulin or to tablets that push the pancreas to release insulin, such as sulfonylureas [1]. When Foundayo™ is started, the label asks prescribers to consider lowering the dose of those medicines and, in people with diabetes, to monitor blood glucose before and during treatment [1]. That is a decision for your prescriber, not something to change yourself.
NIDDK adds general risk factors: taking insulin or certain other diabetes medicines, being 65 or older, having had lows before, and kidney disease, heart disease or cognitive impairment [13]. It names two types of diabetes tablets that can cause lows, sulfonylureas and meglitinides [13]. Before the first tablet, the Medication Guide wants a conversation with your provider about lows and their management, and a mention of any insulin or sulfonylurea [2].
People without diabetes are not exempt. The label says hypoglycemia has been associated with Foundayo™ and other GLP-1 receptor agonists in adults without type 2 diabetes; in Trial 1, 0.6% had glucose below 54 mg/dL, none on placebo, and nobody had a severe episode [1].
Diabetes trials with and against insulin
The ACHIEVE trials tested orforglipron as a diabetes treatment, a use the US label does not include but the European opinion does [1][3]. They used trial doses; only the 36 mg capsule has a stated tablet equivalent, 17.2 mg [8].
| Trial [source] | Design | What was reported |
|---|---|---|
| ACHIEVE-4 [8] | Open label; 2,749 adults at raised heart risk, on up to three of metformin, a sulfonylurea or an SGLT2 inhibitor; orforglipron versus insulin glargine; median 2 years | Glucose below 54 mg/dL or severe: 93 of 1,371 (6.8%) on orforglipron, 260 of 1,355 (19.2%) on glargine |
| ACHIEVE-5 [9][10] | Double blind; 546 adults on titrated insulin glargine; orforglipron 3, 12 or 36 mg or placebo added; 40 weeks | No rise in clinically significant hypoglycemia against placebo; registry lists serious hypoglycemia in 2 of 132 (12 mg) and 1 of 135 (36 mg), none on placebo |
| ACHIEVE-J [11] | Open label; 401 Japanese adults on diet and exercise or one or two oral diabetes medicines; three doses, no comparator; 52 weeks | Level 2 (below 54 mg/dL): 3 of 135 on 12 mg and 3 of 134 on 36 mg; no level 3 (severe) events |
| ACHIEVE-1 [6] and ACHIEVE-2 [7] | Double blind versus placebo with diet and exercise; open label versus dapagliflozin with metformin; 40 weeks | No severe hypoglycemia reported in either trial |
What these trials can and cannot tell you
- ACHIEVE-4 compared orforglipron with insulin, itself a cause of lows, so a lower rate there shows a smaller risk than glargine, not an absence of risk [8].
- ACHIEVE-4 and ACHIEVE-J were open label, so people knew what they took, which can affect reporting [8][11].
- In ACHIEVE-5, participants stayed on titrated insulin glargine throughout [9]. The label’s warning about insulin and its advice to consider lowering the insulin dose still apply in everyday use [1].
- A registry’s serious hypoglycemia entries count events reported as serious adverse events; they do not show how often readings fell below 54 mg/dL [10].
Why the tablet can lower glucose too far
- From the label: orforglipron triggers insulin release when glucose is high, and the label places the extra risk in combination with insulin or insulin secretagogues [1].
- Suggested but not measured: Foundayo™ reduces food intake and can cause vomiting and diarrhoea [1], while NIDDK lists eating too few carbohydrates, skipping or delaying meals, being ill and unable to eat, extra physical activity and alcohol without food as things that lower glucose [13]. How much each contributes on orforglipron has not been studied.
- General knowledge: in people without diabetes, MedlinePlus names alcohol, missing hormones, severe heart, kidney or liver failure, widespread infection, some types of weight-loss surgery and certain non-diabetes medicines among causes of low blood sugar [12].
Signs to recognise
The Medication Guide lists 12 possible signs [2]. Grouped by where you notice them, they are: in the body, shakiness, feeling jittery, sweating, a fast heartbeat, hunger and weakness; in the head and senses, dizziness or light-headedness, headache, blurred vision and slurred speech; and in thinking and mood, confusion or drowsiness and anxiety, irritability or mood changes [2].
MedlinePlus adds that more severe symptoms such as unclear thinking or a seizure appear when glucose is much lower, and that some people get no warning symptoms at all, called hypoglycemic unawareness [12]. NIDDK describes lows during sleep: crying out or nightmares, sweat that dampens the sheets, and waking tired, irritable or confused [13]. Several of these signs overlap with Foundayo™’s own reactions, such as headache, tiredness and dizziness [1], so a meter reading, where you have one, is what tells them apart.
What official sources say to do
MedlinePlus says that if you have diabetes, your provider should teach you how to treat a low; treatment may include a sugary drink, food or glucose tablets, or glucagon if you have been told to use it [12]. Follow the plan your clinician gave you rather than general figures. If symptoms do not improve after a sugary snack, MedlinePlus says to get a ride to the emergency room rather than driving yourself, or to call 911 [12].
For prevention, NIDDK suggests asking your team how to check your glucose and whether a continuous glucose monitor suits you, carrying a fast-acting carbohydrate, eating when you drink alcohol, taking care around exercise and working with your team to adjust the plan [13]. For severe lows that you cannot treat yourself, it describes a glucagon kit, teaching family and friends how to use it and wearing a medical ID [13].
Details specific to the tablet
How far glucose fell in the weight trials is shown in Table 7. In Trial 2, where average HbA1c started at 8%, it dropped by 1.2, 1.4 and 1.7 percentage points on 5.5 mg, 9 mg and 17.2 mg, against 0.4 on placebo; in Trial 1, starting at 5.6%, the drop was 0.3 points on each dose [1].
A fast improvement in glucose has its own warning: section 5.7 says diabetic retinopathy can temporarily worsen, so people with a history of it are monitored, and people with type 2 diabetes are asked to report vision changes [1][2]. Blurred vision can therefore mean two things on Foundayo™, a low in the moment or an eye problem worth checking, and both belong with your provider.
Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- A person with a suspected low who becomes less alert, cannot be woken or has a seizure
Contact: Emergency care (911 or your local emergency number)
- Signs of a low that do not improve after a sugary snack
Contact: Emergency room; get a ride rather than driving, or call 911
MedlinePlus [12]
Today
- Shakiness, sweating, confusion or other signs of a low that settle after treatment, especially on insulin or a sulfonylurea
Contact: Treat it as your clinician taught you, then tell your provider
- Nightmares, sheets damp with sweat, or waking tired and confused
Contact: Your provider, to check for lows during sleep
NIDDK [13]
- Changes in vision during treatment if you have type 2 diabetes
Contact: Your provider
Foundayo™ Medication Guide [2]